Resolvin D1 prevents smoking-induced emphysema and promotes lung tissue regeneration

Kang-Hyun Kim1
Tai Sun Park2,3
You-Sun Kim1,3
Jae Seung Lee2,3
Yeon-Mok Oh2,3
Sang-Do Lee2,3
Sei Won Lee2,3

1Asan Institute for Life Sciences,
2Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center,
3Department of Pulmonology and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, Republic of Korea

Correspondence: Sei Won Lee
Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center,
University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu,
Seoul 05505, Republic of Korea
Tel +82 2 3010 3990
Fax +82 2 3010 6968
Email iseiwon@gmail.com

Purpose: Emphysema is an irreversible disease that is characterized by destruction of lung tissue as a result of inflammation caused by smoking. Resolvin D1 (RvD1), derived from docosahexaenoic acid, is a novel lipid that resolves inflammation. The present study tested whether RvD1 prevents smoking-induced emphysema and promotes lung tissue regeneration.

Materials and methods: C57BL/6 mice, 8 weeks of age, were randomly divided into four groups: control, RvD1 only, smoking only, and smoking with RvD1 administration. Four different protocols were used to induce emphysema and administer RvD1: mice were exposed to smoking for 4 weeks with poly(I:C) or to smoking only for 24 weeks, and RvD1 was injected within the smoking exposure period to prevent regeneration or after completion of smoking exposure to assess regeneration. The mean linear intercept and inflammation scores were measured in the lung tissue, and inflammatory cells and cytokines were measured in the bronchoalveolar lavage fluid.

Results: Measurements of mean linear intercept showed that RvD1 significantly attenuated smoking-induced lung destruction in all emphysema models. RvD1 also reduced smoking-induced inflammatory cell infiltration, which causes the structural derangements observed in emphysema. In the 4-week prevention model, RvD1 reduced the smoking-induced increase in eosinophils and interleukin-6 in the bronchoalveolar lavage fluid. In the 24-week prevention model, RvD1 also reduced the increased neutrophils and total cell counts induced by smoking.

Conclusion: RvD1 attenuated smoking-induced emphysema in vivo by reducing inflammation and promoting tissue regeneration. This result suggests that RvD1 may be useful in the prevention and treatment of emphysema.

Keywords: resolvin D1, COPD, emphysema

Introduction
COPD is a major global health problem, with a prevalence of 5%–25% among adults worldwide.1 COPD is among the top ten most common chronic health conditions and is associated with a marked restriction in daily activity and substantial utilization of health care resources.2 COPD is commonly treated with bronchodilators, which have shown beneficial effects in several clinical trials,3,4 however, bronchodilators act on airways, not lung parenchyma, so the clinical response to treatment is the weakest, among COPD phenotypes, in emphysema, which mainly involves lung parenchyma.5 To reduce hyperinflated lung, lung volume reduction therapy is currently undergoing trial; however, this approach can be applied only to a subset of patients.6,7 Furthermore, no treatment restores damaged lung parenchyma. Considering the paucity of treatments for emphysema, novel approaches are urgently needed.
The resolution of inflammation is now considered a dynamic program that is partially dependent on the equilibrium of leukocyte ingress and egress at inflamed sites.\textsuperscript{8} Resolvin D1 (RvD1), a novel lipid derived from docosahexaenoic acid (DHEA), showed potent anti-inflammatory and proresolving properties in preclinical models of peritonitis,\textsuperscript{9} colitis,\textsuperscript{10} and dermal inflammation,\textsuperscript{11} and recently in aspiration pneumonia\textsuperscript{12} and cigarette smoking-induced lung inflammation.\textsuperscript{13}

The main pathogenesis of emphysema is irreversible lung damage from chronic inflammation induced by smoking. Imbalance between protease and antiprotease is a dominant hypothesis.\textsuperscript{14} Macrophages and neutrophils are main sources of proteases in lungs, and the degree of inflammation induced by these cells correlated with the severity of airflow obstruction.\textsuperscript{15} According to a hypothesis from a UK study, repeated airway infection and hypersecretion of mucus are causes of COPD. In addition, respiratory tract infection is an important cause of acute exacerbation and progression of this disease.\textsuperscript{16} We hypothesized that RvD1, which mediates the resolution of lung inflammation, may prevent emphysema and restore lung tissue by reducing irreversible injury. To test this hypothesis, the effect of RvD1 was assessed in a smoking-induced emphysema model.

Materials and methods

Emphysema mouse model

All the animals used in this study were specific-pathogen-free female C57BL/6 mice (Orient Bio, Seongnam, Republic of Korea) that were of age 8 weeks. All were kept on a 12-hour light and 12-hour dark cycle with free access to food and water. The lung damage from smoking and inflammation is the main pathogenesis of emphysema. Animal models of emphysema were induced by two well-established methods based on this pathogenesis. First, mice were exposed to cigarette smoke for 4 weeks with administration of 50 µg (1 µg/µL) of poly(I:C) via nasal aspiration at 3 weeks and 4 weeks (4-week model).\textsuperscript{17} Second, mice were exposed to cigarette smoke for 24 weeks (24-week model). Cigarette smoke exposure was performed using 12 commercial cigarettes (8.0 mg of tar, 0.80 mg/ cigarette, Eighty Eight Lights; KT&G, Daejeon, Republic of Korea) per day according to a protocol previously described\textsuperscript{18} with modification. In brief, ten to 12 mice were settled in an inhalation box (50 ×40 ×30 cm) connected to a pump and exposed for 10 minutes to mainstream cigarette smoke generated simultaneously from four cigarettes. The mice remained in the box for an additional 10 minutes after the cigarettes had burned. The box was then ventilated to remove the cigarette smoke, and the mice breathed normal room air for 5 minutes. Two additional exposures were performed in the same manner in a day. Control (CTL) or RvD1 only (RE) animals inhaled only clean room air in the cages. The Institutional Animal Care and Use Committee of the Asan Medical Center approved this study (2012-01-176), and all the experiments were performed in accordance with the committee guidelines. Animal care and treatment were guided according to the 8th edition of the Guide for the Care and Use of Laboratory Animals.

Experimental design

Four different administration protocols of RvD1 (Caymen, Ann Arbor, MI, USA; 100 ng or phosphate buffered saline [PBS] of the same volume) were performed. In the first protocol, RvD1 or PBS was injected in the tail vein 3 weeks and 4 weeks after the start of smoking exposure in the 4-week model. One day after the completion of the 4 weeks smoking exposure, mice were sacrificed (4-week prevention model; Figure 1A). In the second protocol, RvD1 or PBS was injected in the tail vein 4 weeks and 5 weeks after the start of smoking exposure in the 4-week model. Two weeks after the completion of the 4-week smoking exposure, mice were sacrificed (4-week regeneration model; Figure 1B). In the third protocol, RvD1 or PBS was injected at 18 weeks, 20 weeks, 22 weeks, and 24 weeks after the start of smoking exposure in the 24-week model. One day after the completion of the 24-week smoking exposure, mice were sacrificed (24-week prevention model; Figure 1C). In the fourth protocol, RvD1 or PBS was injected at 0 week, 2 weeks, 4 weeks, and 6 weeks after the completion of smoking exposure in the 24-week model. Eight weeks after the completion of the 24-week smoking exposure, mice were sacrificed (24-week regeneration model; Figure 1D). Each model included four groups: CTL, RE, smoking only (SM), and smoking exposure and RvD1 (SR).

Bronchoalveolar lavage

Mice were sacrificed using 40 mg/kg of Zoletil (Virbac, Carros, France) and 10 mg/kg of Rompun (Bayer AG, Leverkusen, Germany). The trachea was catheterized and perfused with two 0.6 mL and one 0.7 mL aliquot of cold saline. The cellular and liquid fractions of bronchoalveolar lavage (BAL) fluid were separated by centrifugation (2,200 rpm at 4°C for 5 minutes). The cell pellet was suspended, seeded onto a slide, and stained with Diff-Quick (Sysmex, Kobe, Japan). The BAL liquid fractions were stored in aliquots at −80°C pending cytokine measurement.

Quantification of cytokines in cell culture supernatant and BAL fluid

The levels of interleukin-6 (IL-6) in the culture supernatants and BAL fluids were measured with a commercially available
ELISA kit (Merck Millipore, Billerica, MA, USA) using fluorescently labeled microsphere beads and a Luminex 100/200™ (Luminex Co., Austin, TX, USA) reader.

**Histologic analysis**

The left main bronchus was ligated, and the right lung was inflated with 0.5% low temperature melting agarose at a pressure of 15 cmH₂O.¹⁹ The lungs were then fixed with 3.5% formalin, embedded in paraffin, cut into 5 µm thick sections, and stained with hematoxylin and eosin. The mean linear intercept (MLI) was measured as described previously.²⁰ In brief, the average interalveolar septal wall distances were determined by the number of interruptions in 1 mm lines of alveolar wall. Any line that crossed a large vessel or bronchus was excluded from evaluation. Four or more lines were drawn in each field, and at least three random fields were examined per mouse. The degree of peribronchial and perivascular inflammations was scored on a subjective scale of 0 (no) to 4 (severe) in a blind manner. Each scoring was performed with the comparison of the standardized figures presenting grades. The inflammation score was defined as the sum of the peribronchial and perivascular scores (0–8).²¹,²² Histologic analyses were performed in different mice than those used for BAL.

**Statistical analysis**

All values were represented as mean ± standard deviation. Differences between multiple groups were analyzed by one-way analysis of variance with Tukey’s post tests or two-way analysis of variance with Bonferroni post tests. Significance was defined by a P-value of 0.05. All statistical calculations were conducted in GraphPad Prism Version 5.03 for Windows (GraphPad Software, Inc., La Jolla, CA, USA).

**Results**

Inhibition of cigarette smoke induced emphysema development by RvD1

We first evaluated the effects of RvD1 using four different experimental protocols as described previously. In all the four models, cigarette smoke induced lung parenchymal destruction and airspace enlargement leading to increased MLI. RvD1 administration attenuated lung destruction significantly. In the 4-week prevention and regeneration models, the MLIs of the SM and SR groups were 50.75±4.09 µm vs 43.52±2.89 µm (P<0.05) and 49.42±2.82 µm vs 42.94±3.24 µm (P<0.01), respectively. In the 24-week prevention and regeneration models, the MLIs of the SM and SR groups were 52.46±4.17 µm vs 45.25±1.47 (P<0.01) and 49.22±4.51 µm vs 40.44±3.02 µm.
Reduction of peribronchial and perivascular inflammatory cell infiltration by RvD1

Inflammatory cell infiltration contributes to structural derangements in COPD via the release of proteases and reactive oxygen species. Therefore, we tested the effect of RvD1 on inflammatory cell infiltration induced by smoking. In all models, smoking caused inflammatory cell infiltration in perivascular and peribronchial areas. RvD1 inhibited inflammatory cell infiltration consistently in all four models. Histologic score in the SR group showed a significant decrease in smoking-induced inflammatory cell infiltration. No difference in histologic scores was observed between the CTL and RE groups (Figure 3).

RvD1 reduced eosinophil counts and IL-6 in the BAL fluid in the 4-week prevention model

Chronic exposure to smoking significantly increased total cell counts, eosinophil counts, and neutrophil counts in the BAL fluid compared to the CTL group in the 4-week prevention model. RvD1 reduced eosinophil counts significantly in the SR group compared to the SM group (9.79±1.16 [×10^5]/mL vs 5.47±1.54 [×10^5]/mL, P<0.001). Neutrophil counts were also reduced in the SR group compared to the SM group without reaching statistical significance (2.32±1.00 [×10^5]/mL vs 1.63±0.80 [×10^5]/mL, P>0.05). No significant difference in total cell counts was observed between the SM and SR groups. In the 4-week prevention model, IL-6 was also increased in the BAL fluids of the SM group compared to those of the CTL group, and the IL-6 level was decreased significantly in the SR group compared to that in the SM group (1,008.02±247.65 pg/mL vs 598.51±161.94 pg/mL, P<0.01; Figure 4).

RvD1 reduced total cell counts and neutrophil counts in the BAL fluid in the 24-week prevention model

Chronic exposure to smoking also significantly increased total cell counts, eosinophil counts, and neutrophil counts in the BAL fluid compared to those in the CTL group in the 24-week prevention model. RvD1 reduced the total cell count and neutrophil count significantly in the SR group compared to those in the SM group (total cell count: 4.19±0.47 cells [×10^5]/mL vs 3.28±0.75 cells [×10^5]/mL, P<0.05; neutrophil count: 0.87±0.34 cells [×10^5]/mL vs 0.45±0.14 cells [×10^5]/mL, P<0.001). No significant difference in the eosinophil count was observed between the SM and SR groups (0.15±0.03 cells [×10^5]/mL vs 0.17±0.06 cells [×10^5]/mL, P>0.05). In the 24-week prevention model, IL-6 levels of the BAL fluid were reduced in the SR group compared to those in the SM group without reaching statistical significance (Figure 5). IL-6 was not detected in the 24-week regeneration models (data not shown).

Discussion

This study showed that RvD1 can protect against the alveolar destruction induced by chronic exposure to smoking. RvD1 attenuated the inflammation caused by cigarette smoking. These results indicate that RvD1 can prevent smoking-induced lung damage and has possibility to regenerate lung tissue.

RvD1 is a lipid that promotes the resolution of inflammation, which is quite important to return to homeostasis. Unresolved chronic inflammation can cause tissue damage and fibrosis, followed by decreased function. RvD1 has already shown benefits in pulmonary infectious and allergic disease models by reducing inflammation. Resolvin E1 protects against acid-initiated acute lung injury and pneumonia by blocking neutrophil trafficking and proinflammatory mediator release. RvD1 attenuates lung inflammation in lipopolysaccharide-induced acute lung injury by suppressing nuclear factor-kappa B activation. Resolvin E1 inhibits bronchial hyperresponsiveness, mucus secretion, and eosinophil recruitment in an ovalbumin-sensitized asthma model. A recent report showed that RvD1 resolves cigarette smoke-induced lung inflammation in the acute phase. In human alveolar macrophages, resolvin decreased inflammatory cytokines and enhanced phagocytosis. Considering this body of evidence, resolvin may provide therapeutic benefit in emphysema, an inflammatory disease induced by chronic exposure to smoking, and a recent study supports this. Meanwhile, there were no reports of therapeutic resolvin administration in emphysema in human beings. The present study provides the novel evidence that the beneficial effect of resolvin on smoking-induced emphysema is consistent in various models, and it can be the basis for future human trials.

Although little is known about the role of resolvin in human beings, several indirect lines of evidence support beneficial effects in respiratory diseases. Enteric feeding of supplements enriched in omega-3 polyunsaturated fatty acids (a precursor of resolvin) improves clinical outcomes in acute
Figure 2: Measurements of emphysema assessed by MLI.

Notes: RvD1 reduced smoking-induced increase in MLI in all four models: (A) 4-week prevention, (B) 4-week regeneration, (C) 24-week prevention, and (D) 24-week regeneration models. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Tukey’s post tests). The scale bars indicate 100 µm. The results are presented as the mean of the mice included in all experiments.

Abbreviations: MLI, mean linear intercept; RvD1, resolvin D1; ANOVA, analysis of variance; CTL, control; RE, RvD1 only; SM, smoking; SR, smoking + RvD1.
Figure 3 Degree of inflammatory cell infiltration.

Notes: Histologic scoring indicates that smoking significantly increased peribronchial and perivascular inflammatory cell infiltrations and that infiltration was reduced by resolvin D1 in the (A) 4-week prevention, (B) 4-week regeneration, (C) 24-week prevention, and (D) 24-week regeneration models. **p < 0.01 and ***p < 0.001 (one-way ANOVA with Tukey’s post tests). The scale bars indicate 100 µm.

Abbreviations: ANOVA, analysis of variance; CTL, control; RE, RvD1 only; RvD1, resolvin D1; SM, smoking; SR, smoking + RvD1.
Resolvin in emphysema treatment

Figure 4 BAL fluid analysis in the 4-week prevention model.
Notes: RvD1 significantly reduced the smoking-induced increase in (A) total cell counts, (B) eosinophil counts, and (C) IL-6 levels in the BAL fluid. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Tukey’s post tests).
Abbreviations: BAL, bronchoalveolar lavage; RvD1, resolvin D1; IL6, interleukin-6; ANOVA, analysis of variance; CTL, control; RE, RvD1 only; SM, smoking; SR, smoking + RvD1; Mac, macrophage; Lym, lymphocyte; Eos, eosinophil; Neu, neutrophil.

Figure 5 BAL fluid analysis in the 24 week prevention model.
Notes: RvD1 significantly reduced the smoking-induced increase in (A) total cell counts and (B) neutrophil counts. (C) The IL-6 level in the BAL fluid also decreased, but statistical significance was not reached because the basal level was too low. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Tukey’s post tests).
Abbreviations: BAL, bronchoalveolar lavage; RvD1, resolvin D1; IL6, interleukin-6; ANOVA, analysis of variance; CTL, control; RE, RvD1 only; SM, smoking; SR, smoking + RvD1; Mac, macrophage; Lym, lymphocyte; Eos, eosinophil; Neu, neutrophil.
respiratory distress syndrome by reducing time to liberation from mechanical ventilation and discharge from the intensive care unit.29 A high intake of eicosapentaenoic acid (EPA) and DHEA was inversely correlated with the risk of COPD in smokers, suggesting a protective effect against smoking.30 EPA and DHEA supplementation also significantly attenuates the allergen-induced asthmatic response.31 Japanese workers, who have a higher fish consumption than their American counterparts, have a lower incidence of chronic bronchitis and a higher mean forced expiratory volume in 1 second than their American counterparts despite equivalent levels of cigarette smoking.32

RvD1 attenuated the MLI increased by smoking in the 4-week and 24-week models and also decreased inflammatory cell counts in the BAL fluid; however, BAL fluids differed in their composition of inflammatory cells: differences in eosinophil counts were prominent in the 4-week models, whereas differences in neutrophil counts were observed in the 24-week models. New-onset smoking is a significant risk factor for acute eosinophilic pneumonia,33 which is characterized by acute and organizing diffuse alveolar damage with eosinophil infiltration.34 Acute eosinophilic pneumonia is the only well-established respiratory disease that develops in the initiation phase of smoking; therefore, eosinophil accumulation may be an important pathogenic feature of the inflammatory process in this phase. This suggests that the duration, time, and method of smoking can make a difference in alveolar cell composition. During chronic exposure to smoking, neutrophils are the main contributors to lung destruction, especially in emphysema.35,36 Cigarette smoke disrupts normal neutrophil apoptosis and efferocytosis. Impairment of neutrophil clearance can lead to irreversible local tissue damage via production of mediators, including neutrophil elastase and reactive oxygen species.37 Considering the result of our study, resolvin can attenuate lung damage by reducing key inflammatory cells in both the initial and late phases of smoking. RvD1 also decreased the smoking-induced increase in IL-6; however, no statistical significance was reached in the 24-week model. Although smoking increases neutrophils in the BAL fluid over time,38 the increase in inflammatory cytokines usually falls off after the acute phase of inflammation, which persists for several days.39 The elevation in inflammatory cytokines such as IL-6 by chronic exposure to smoking does not seem high enough to reach statistical significance. Other cytokines such as interleukin-8 and interleukin-1 beta can have a role in the recruitment of neutrophils in chronic smoking. Meanwhile, the inflammation score suggested that chronic inflammatory change still persisted even after the recruitment of inflammatory cells has reduced. These histologic changes from chronic exposure to smoking might include fibrosis, bronchial wall thickening, or vascular remodeling.

To restore destroyed and injured lung is the ultimate goal of emphysema treatment, but this is not achieved by the current treatment. Pharmacologic treatment of COPD involves bronchodilators, which aim to decrease airway resistance; this treatment shows limited effectiveness against decreased elastic recoil and hyperinflation, which is the main pathogenesis of emphysema. Smoking-related inflammation persists for several years even after smoking cessation, and COPD not only persists but may also continue to worsen.40 A limited number of anti-inflammatory therapies, including a phosphodiesterase-4 inhibitor and a steroid, are available; however, long-term steroid use carries risks of adverse effects that potentially outweigh benefits,41 and phosphodiesterase-4 inhibitors benefit mainly in chronic bronchitis.42 In this context, our findings have implications for the treatment of emphysema and future clinical trials. Proresolving lipid mediators such as resolvin and its precursors, including EPA and DHEA, might be therapeutically useful to protect from and reduce lung injury in diseases induced by chronic smoke exposure such as COPD. Resolvin has a significant clinical potential because it promotes inflammation resolution and tissue repair without being immunosuppressive.

However, we should keep in mind that several kinds of molecules that improved emphysema in animal models failed to show efficacy in human beings. Simvastatin inhibits cigarette smoking-induced emphysema in rats,22 and several retrospective studies suggested that statins could also be beneficial in human beings.43,44 Unfortunately, no reduction in COPD exacerbation was observed in a large randomized trial.45 Several other treatments, including vitamin C,46 angiotensin receptor blockade,47 and stem cells,48 attenuated smoke-induced emphysema in animals, but these effects have not been reproduced in human beings yet. Therefore, proresolving lipids should be tested in human trials. For a successful human study, the appropriate target population should be selected and the most effective administration protocols should be used. It is not clear whether nutritional supplementation with fish oil or omega-3 polyunsaturated fatty acids is enough or whether injections of more refined forms, such as resolvin or protectin, is necessary.

**Conclusion**

RvD1 attenuated smoking-induced emphysema and showed possibility to regenerate lung tissue by reducing...
inflammatory cells and cytokines. Although the exact mechanism should be elucidated further, these findings indicate that resolvin may play a role in the treatment of cigarette smoking-induced COPD.

Acknowledgment
This study was supported by a grant (2013-553) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.

Author contributions
All authors contributed toward data collection, statistical analysis, drafting and critically revising the paper, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


42. Rennard SJ, Calverley PM, Goehringer UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. *Respir Res*. 2011;12:18.


